Ally Bridge Group (Ny) LLC Atea Pharmaceuticals, Inc. Transaction History

Ally Bridge Group (Ny) LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.17 $2.62 Million - $3.72 Million	602,694 Added 167.42%	962,694 $4.63 Million
Q3 2022 Nov 14, 2022	BUY	$5.49 - $8.79 $1.98 Million - $3.16 Million	360,000 New	360,000 $2.05 Million
Q3 2021 Nov 15, 2021	SELL	$21.33 - $35.06 $7.96 Million - $13.1 Million	-373,288 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$19.22 - $59.08 $10.2 Million - $31.3 Million	-530,400 Reduced 58.69%	373,288 $8.02 Million
Q1 2021 May 17, 2021	SELL	$41.42 - $88.44 $4.68 Million - $9.99 Million	-113,000 Reduced 11.11%	903,688 $55.8 Million
Q4 2020 Feb 16, 2021	BUY	$26.36 - $41.78 $26.8 Million - $42.5 Million	1,016,688 New	1,016,688 $42.5 Million

109

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $255M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.